Responsibility in Drug Advertising Act of 2024

This bill prohibits direct-to-consumer advertising of newly approved prescription drugs for the first three years after approval, including on social media. Drug manufacturers may request a waiver for the third year if they demonstrate public health benefits to the FDA. After the initial three years, the FDA can ban advertising if post-approval studies show significant health risks. The law applies to drugs approved under standard FDA review processes, directly affecting pharmaceutical companies and consumer access to advertising for new medications.